Pricing Log in Create free account
Friday 6 November 2026 Export AORT’s income statement to Excel — free account

Artivion, Inc.

AORT Healthcare Medical Devices

Artivion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $441.3 million, up 13.6% from fiscal 2024.

Revenue
+9.17%
EPS
−214.3%
Free cash flow
−202.5%
Total debt
+68.2%

Quarter to September 2026, against a year earlier

20.40 4.93 −19.46%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−64.5×
Dividend yield
—
F-score
7/9
Altman Z
3.73
Beneish M
−2.38
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 12.06
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 5 — 6 12 — — 1 — 4 2 — —
Insider Ownership 5.25%

Capital & Financial Ratios $m

Size
Market Cap 1,230.00
Revenue ttm 481.88
Net income ttm (17.59)
Free cash flow ttm (44.38)
Net debt Q 317.96
Valuation
P/E 0.00
Forward P/E (64.50) (negative: loss-making)
Price / sales 2.09
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.26
Financial health
Current ratio Q 4.42 (at or above 1.5: strong)
Debt / equity Q 0.82
Interest coverage Q 0.35
Growth
Revenue growth Q +9.17% (above 0%: growing)
Operating income growth Q −76.49% (below 0%: shrinking)
EPS, this year −228.57% (below 0%: weak)
EPS, next year A +206.94% (at or above 15%: strong)
Revenue, next year A +11.16% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +30.11% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 3.6×; over the ten years it ranged from 1.6× in 2016 to 6.5× in 2018.
P/S against its own 10 years 13.45%
10-year low 10-year high
P/B against its own 10 years 17.67%
10-year low 10-year high
EV/Sales against its own 10 years 15.51%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 59 53 65 48
Receivables 74 86 104 106
Inventory 82 80 92 107
Other — — — —
281 290 358 339
2023 2024 2025 Q'26
Payables 13 18 16 18
ST’ Debt 1 0 — —
Other 2 1 25 —
58 67 102 77

Compound Annual Growth %

10y 5y 3y
Sales 11.70% 11.75% 12.04%
Cash Flow 13.30% 26.38% 0.00%
Earnings 9.55% 0.00% 0.00%
Book Value 11.19% 6.40% 16.38%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.13 Actual 0.13

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.14 0.16 Beat by 0.02
Q4 FY25 0.14 0.17 Beat by 0.03
Q1 FY26 0.06 0.08 Beat by 0.02
Q2 FY26 0.13 0.13 Met by 0.00
Q3 FY26 0.11 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.03 (0.28) (0.16) — —
’25 (0.01) 0.03 0.13 0.05 0.21
’24 0.18 (0.05) (0.05) (0.39) (0.32)
’23 (0.33) (0.08) (0.24) (0.10) (0.75)
’22 (0.08) (0.11) (0.34) 0.05 (0.48)
’21 (0.08) (0.06) 0.26 (0.51) (0.38)
’20 (0.18) (0.10) (0.08) (0.09) (0.44)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 116 126 124 — —
’25 99 113 113 116 441
’24 97 98 96 97 389
’23 83 89 88 94 354
’22 77 80 77 79 314
’21 71 76 72 79 299
’20 66 54 65 68 253
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 1 (1) (5) — —
’25 (17) 15 22 20 40
’24 (5) 6 11 10 22
’23 (6) 7 7 11 19
’22 (1) (8) 4 0 (5)
’21 (3) 3 (3) 1 (3)
’20 3 (3) 8 5 12
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (7) (12) (18) — —
’25 (21) 12 18 (8) 1
’24 (9) 4 8 9 11
’23 (10) 5 5 8 9
’22 (3) (10) 0 (6) (18)
’21 (5) (3) (7) (2) (17)
’20 0 (5) 6 2 4
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 180 190 263 276 253 299 314 354 389 441 482 +10.5% 491 544 610 +11.4%
Gross margin, % 65.92 67.81 65.81 66.26 66.26 66.09 64.54 64.74 64.03 64.40 63.31 (1.5) pt
EBT 18 4 (6) 2 (17) (15) (15) (22) (8) 15 (11) (2.4%)
EBT margin, % 10.21 1.88 (2.43) 0.60 (6.78) (4.96) (4.78) (6.10) (1.93) 3.35 (2.23) (6.9) pt
Net income 11 4 (3) 2 (17) (15) (19) (31) (13) 10 (18) (1.1%)
Per share, $
Per share, $ Revenue 5.66 5.75 7.22 7.44 6.69 7.67 7.84 8.69 9.32 9.73 9.89 +6.2%
Earnings 0.33 0.11 (0.08) 0.05 (0.44) (0.38) (0.48) (0.75) (0.32) 0.22 (0.36) (4.4%)
Cash flow 0.62 0.33 0.27 0.43 0.33 (0.07) (0.13) 0.46 0.53 0.88 0.31 +4.0%
Capex (0.19) (0.20) (0.16) (0.22) (0.22) (0.36) (0.31) (0.24) (0.27) (0.86) (1.22) +18.0%
Free cash flow 0.42 0.13 0.11 0.21 0.10 (0.43) (0.44) 0.22 0.27 0.02 (0.91) (29.4%)
Book value 6.56 8.39 7.55 7.70 8.68 7.71 7.10 6.92 6.63 9.89 9.16 +4.7%
Shares, m 32 33 36 37 38 39 40 41 42 45 48 +4.0%
Valuation, ×
Valuation, × P/E 57.58 173.64 0.00 583.84 0.00 0.00 0.00 0.00 0.00 217.19 0.00 103.2
P/S 3.36 3.32 3.93 3.64 3.53 2.65 1.50 2.07 3.07 4.69 2.09 3.2
P/B 2.90 2.28 3.76 3.52 2.72 2.64 1.66 2.60 4.31 4.61 2.26 3.1
EV/Sales 3.43 4.30 4.62 4.32 4.46 3.52 2.37 2.78 3.75 5.03 2.75 3.9
EV/FCF 45.82 195.52 296.45 153.76 223.94 (58.43) (38.32) 189.92 203.47 (726.43) (27.47) 48.6
Cash, $m
Cash, $m Operating cash flow 20 11 10 16 12 (3) (5) 19 22 40 15 +8.1%
Capex (6) (7) (6) (8) (8) (14) (12) (10) (11) (39) (59) +22.7%
Free cash flow 14 4 4 8 4 (17) (18) 9 11 1 (44) (26.6%)
Balance, $m
Balance, $m Working capital 117 136 145 142 174 203 198 223 223 257 262 +9.1%
Net debt 14 185 181 187 235 258 272 251 264 153 318 +30.2%
Shareholders’ equity 209 277 275 286 329 301 284 282 276 448 446 +8.8%
Returns, %
Returns, % ROA 4.25 0.80 (0.48) 0.29 (2.38) (1.86) (2.45) (3.93) (1.69) 1.17 0.00 (3.1) pt
ROIC 6.11 1.08 1.28 2.25 0.27 0.91 0.70 0.67 4.50 3.51 0.90 (2.6) pt
ROE 5.80 1.50 (1.02) 0.61 (5.39) (4.68) (6.53) (10.80) (4.78) 2.69 0.00 (3.1) pt
People
People Employees 665 1,000 1,100 1,200 1,200 1,300 1,300 1,500 1,600 1,800 — +11.7%
Revenue/emp, $m 0.27 0.19 0.24 0.23 0.21 0.23 0.24 0.24 0.24 0.25 — (1.1%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Artivion, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ENOV Enovis Corporation $1.7B — (loss-making) 98.6× +1.79% (above 0%: growing) n/m +20.30% (above 0%: growing) 60.83% 0.60% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.3B — (loss-making) 38.0× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
TNDM Tandem Diabetes Care, Inc. $1.3B — (loss-making) — (loss-making) +13.82% (above 0%: growing) n/m −231.98% (below 0%: shrinking) 56.55% (0.84%) Compare
AORT Artivion, Inc. $1.2B — (loss-making) — (loss-making) +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%)
ATEC Alphatec Holdings, Inc. $1.2B — (loss-making) — (loss-making) +12.55% (above 0%: growing) n/m −149.22% (below 0%: shrinking) 71.55% 1.47% Compare
PRCT PROCEPT BioRobotics Corporation $1.2B — (loss-making) — (loss-making) +17.96% (above 0%: growing) n/m −1.57% (below 0%: shrinking) 66.28% (27.85%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B 83.0× 26.0× +2.27% (above 0%: growing) n/m +232.94% (above 0%: growing) 51.04% 4.60% Compare
IRMD iRadimed Corporation $1.1B 44.9× 39.6× +14.15% (above 0%: growing) +15.91% (above 0%: growing) +18.58% (above 0%: growing) 76.26% 33.63% Compare
SIBN SiBone $1.1B — (loss-making) — (loss-making) +14.49% (above 0%: growing) n/m +31.13% (above 0%: growing) 79.29% (7.81%) Compare
Median of peers $1.2B — 38.8× +13.19% — +19.44% 63.56% 1.04%

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 1 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 6.88m 17.44m 193.00
2024 5.51m 12.33m 121.00
2023 3.18m 7.23m 76.00
2022 7.22m 4.72m 51.00
2021 4.63m 3.71m 86.00

Ownership

Directors and executive officers, together 6.30%
Blackrock, Inc. 12.70%
The Vanguard Group, Inc. 6.40%
Nomura Investment Management Business Trust 5.50%
FMR LLC 5.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Artivion, Inc. (AORT) Latest News

6 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · Simply Wall St.
Impact 3 · · The Motley Fool transcript

5 Nov

Impact 3 · · Associated Press
Impact 3 · · PR Newswire

28 Oct

Impact 3 · · PR Newswire

22 Oct

Impact 3 · · StockStory

20 Oct

Impact 4 · · Investing.com
Impact 3 · · Simply Wall St.

15 Sep

Impact 3 ·

27 Aug

Impact 4 ·

15 Aug

Impact 3 ·

13 Aug

Impact 3 · · The Motley Fool transcript

11 Aug

Impact 4 ·

7 Aug

Impact 4 · transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·

6 Aug

Impact 3 ·
Impact 3 ·

1 Jul

Impact 4 ·

29 Jun

Impact 4 ·

12 Jun

Impact 3 ·

20 May

Impact 3 · · Simply Wall St.

19 May

Impact 4 · · Simply Wall St.

18 May

Impact 4 · · medtechdive.com
Impact 4 · · medicaldevice-network.com
Impact 4 · · Business Wire
Impact 4 · · PR Newswire

17 May

Impact 3 · · StockStory

11 May

Impact 4 · · StockStory
stockrow.com/AORT · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com